CYTR - CytRx Corporation

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.54
-0.03 (-1.91%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.57
Open1.56
Bid1.65 x 1500
Ask1.71 x 100
Day's Range1.51 - 1.62
52 Week Range1.50 - 6.00
Volume193,797
Avg. Volume343,942
Market Cap42.562M
Beta1.69
PE Ratio (TTM)N/A
EPS (TTM)-1.79
Earnings DateMar 13, 2018 - Mar 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.00
Trade prices are not sourced from all markets
  • PR Newswire13 days ago

    CytRx Corporation to Present at the 2018 BIO CEO & Investor Conference

    LOS ANGELES, Feb. 6, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present at the 2018 BIO CEO & Investor Conference on Monday, February 12th at 10:15 a.m. Eastern Time at the New York Marriott Marquis Hotel. Presentation dates and times, along with any links to potential webcasts for the Roth Conference, will be provided closer to the actual event. The 2018 BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

  • PR Newswire14 days ago

    CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma

    LOS ANGELES, Feb. 5, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with advanced squamous cell carcinoma (SCC) of either the head and neck or non-small cell lung cancer.  This is the second trial conducted by NantCell which will investigate high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in certain high unmet need cancer indications.  The first trial in pancreatic cancer patients commenced in January 2018. The trial titled "QUILT-3.090: Molecularly Informed Integrated Immunotherapy in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programed Death Ligand 1 (PD-L1) Therapy," (NCT03387111) is a single-center, open-label, Phase 1b/2 clinical trial designed to evaluate the safety and efficacy of several combination therapies, including combinations with aldoxorubicin, in subjects with SCC who have progressed on or after platinum-based chemotherapy and anti-PD1/PD-L1 therapy.  This trial is expected to enroll approximately 65 patients.  The primary endpoint for the Phase 1b portion of the trial is safety and the primary endpoint for the Phase 2 portion of the trial is objective response rate (ORR) by RECIST.

  • ACCESSWIRE26 days ago

    Today’s Research Reports on Stocks to Watch: Inovio Pharmaceuticals and CytRx Corporation

    NEW YORK , NY / ACCESSWIRE / January 24, 2018 / Inovio was one of the best performing stocks in the market yesterday after the company revealed published data that was encouraging regarding its goal of ...

  • PR Newswirelast month

    CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer

    LOS ANGELES, Jan. 17, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with metastatic pancreatic cancer.  The trial will investigate high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in metastatic pancreatic cancer patients who have progressed on or following standard-of-care therapy. "NantCell's decision to include aldoxorubicin in this new trial speaks to their commitment to expanding its potential use in combination with immuno-oncology agents and cell-based therapies," said Steven A. Kriegsman, CytRx's Chairman and CEO.

  • PR Newswire2 months ago

    CytRx Corporation to Present at Biotech Showcase 2018

    LOS ANGELES , Jan. 3, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven ...

  • PR Newswire2 months ago

    CytRx Corporation Provides Update on Presentations at Upcoming Investor Conferences

    LOS ANGELES , Dec. 7, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its presentation scheduled ...

  • PR Newswire2 months ago

    CytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR™ Drug Candidates

    LOS ANGELES, Dec. 6, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has filed provisional patent applications covering two series of drug candidates from its LADR™ (Linker Activated Drug Release) Technology Platform.  The newly filed applications cover compounds, pharmaceutical compositions and methods of use thereof.  When granted, these new patents will expand CytRx's intellectual property estate and the Company will own worldwide rights for each.

  • PR Newswire3 months ago

    CytRx Corporation to Present at Upcoming Investor Conferences

    LOS ANGELES , Nov. 27, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO, Steven ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and CytRx Corporation

    NEW YORK, NY / ACCESSWIRE / November 20, 2017 / Eleven Biotherapeutics shares moved higher on Friday as investors continued to cheer the company's update last week in its earnings call about its Vicinium ...

  • PR Newswire3 months ago

    CytRx Corporation Regains Nasdaq Listing Compliance

    LOS ANGELES, Nov. 17, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it received written notification on November 16, 2017, from the NASDAQ Listing Qualifications Department that it has regained compliance with the minimum bid price requirement set forth in NASDAQ Listing Rule Section 5550(a)(2) for continued listing of its common stock on The NASDAQ Capital Market. Separately, CytRx has engaged the services of a third party firm to conduct an in-depth investigation to determine the extent of short-selling (both institutional and naked) in the Company's common stock. The investigation firm will also look into the possible intent to manipulate the value of CytRx shares, including information concerning erroneous statements from bloggers, postings to CytRx message boards and other questionable practices.

  • PR Newswire3 months ago

    CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives

    LOS ANGELES, Nov. 13, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today provided a business update and announced new shareholder relations initiatives. Going forward, CytRx will be implementing a number of initiatives designed to enhance transparency and increase the frequency of communication with its shareholders.  First, the Company plans to conduct quarterly conference calls, starting with the filing of its year end 2017 financials (Form 10-K) in March 2018 and then for subsequent quarterly filings.  The Company will also be making more frequent updates to its corporate website.

  • Associated Press3 months ago

    CytRx reports 3Q loss

    On a per-share basis, the Los Angeles-based company said it had a loss of 19 cents. Losses, adjusted for non-recurring gains, were 33 cents per share. The company's shares closed at $1.93. A year ago, ...

  • PR Newswire3 months ago

    CytRx Reports Third Quarter 2017 Financial Results

    LOS ANGELES , Nov. 8, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ...

  • Is CytRx Corporation’s (CYTR) Balance Sheet A Threat To Its Future?
    Simply Wall St.3 months ago

    Is CytRx Corporation’s (CYTR) Balance Sheet A Threat To Its Future?

    CytRx Corporation (NASDAQ:CYTR) is a small-cap stock with a market capitalization of USD $59.70M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • PR Newswire3 months ago

    CytRx Announces Strategic Realignment of Clinical Development Team

    LOS ANGELES, Nov. 6, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the strategic realignment of its drug development efforts for advancing new drug candidates based on its LADR™ (Linker Activated Drug Release) Technology Platform.  Going forward, CytRx's drug development, manufacturing and regulatory activities will be led by Hurley Consulting Associates Ltd., an international consulting organization based in Summit, New Jersey, which has been providing strategic consulting to the Company since 2015.

  • PR Newswire4 months ago

    CytRx Corporation Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology Pipeline

    LOS ANGELES, Nov. 2, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted recent progress achieved by its discovery laboratory with its innovative LADR™ (Linker Activated Drug Release) Technology Platform and provided an update for its oncology pipeline.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Stocks to Watch: CytRx Corporation and Skyline Medical

    NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Shares of CytRx closed up higher on Wednesday, the day the company's 1-for-1 reverse stock split took effect. Shares of Skyline Medical also advanced on tremendous ...

  • PR Newswire4 months ago

    CytRx Corporation Announces Reverse Stock Split

    LOS ANGELES, Oct. 31, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the previously disclosed 1-for-6 reverse stock split of its issued and outstanding common stock will become effective as of the commencement of trading on Wednesday, November 1, 2017 (the "Effective Time").  The split-adjusted shares of CytRx's common stock will continue trading on the Nasdaq Capital Market under the Company's existing symbol "CYTR."  A new CUSIP number of 232828608 has been assigned to the Company's common stock as a result of the reverse split.

  • PR Newswire4 months ago

    CytRx Corporation Announces Results from Special Meeting of Stockholders

    CytRx plans to implement the reverse stock split next week, subject to confirmation of the record date with Nasdaq.  In order to regain compliance with Nasdaq's $1.00 bid price standard, the Company must demonstrate a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days following the reverse stock split.

  • PR Newswire4 months ago

    Lifshitz & Miller LLP Announces Investigation of Antares Pharma, Inc., CenturyLink, Inc., CytRx Corporation, Dentsply Sirona, Inc., Dr. Reddy's Laboratories Limited, J.Jill, Inc., and Navient Corporation

    NEW YORK , Oct. 24, 2017 /PRNewswire/ -- Antares Pharma, Inc. (ATRS) Lifshitz & Miller announces an investigation on behalf of ATRS investors concerning whether ATRS issued false and misleading statements ...

  • PR Newswire4 months ago

    CytRx Corporation Announces Outcome of Nasdaq Hearing

    On or before October 30, 2017, the Company shall inform the Panel that is has received stockholder approval to implement a reverse stock split in a ratio of 1 for 6 shares. On or before November 15, 2017, the Company must evidence a closing bid price of $1.00 or more for a minimum of ten prior consecutive trading days.

  • PR Newswire4 months ago

    CytRx Corporation Highlights Inclusion of Aldoxorubicin in Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell, Inc.

    LOS ANGELES , Oct. 12, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee ...

  • PR Newswire5 months ago

    Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors Encouraged to Contact Firm

    Shareholder Rights Law Firm Johnson Fistel, LLP today announced that it is investigating whether certain officers or directors of NantKwest, Inc. (NK) ("NantKwest") violated federal or state laws. On September 20, 2017, a federal court denied a motion to dismiss a securities fraud class action filed against the company and certain executives.

  • PR Newswire5 months ago

    Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote "FOR" the Proposed Reverse Stock Split

    LOS ANGELES, Oct. 4, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Institutional Shareholder Services, Inc. (ISS), the leading global independent proxy advisory firm, issued a report on September 28, 2017, recommending that CytRx stockholders vote "FOR" the proposed reverse stock split at the upcoming special meeting of stockholders scheduled for October 17, 2017 at 10:00 a.m. PT. ISS is the most prominent independent proxy voting and corporate governance advisory firm, and its recommendations are relied upon by institutional investment firms, mutual funds and other fiduciaries globally.  ISS' experienced research team provides comprehensive proxy analyses and complete vote recommendations for approximately 40,000 meetings annually in around 117 markets worldwide.

  • PR Newswire5 months ago

    CytRx Corporation Provides Business Update and Highlights Future Plans

    LOS ANGELES, Oct. 2, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today provided a business update and highlighted the Company's future plans. During 2017, CytRx has made significant strides in advancing its lead oncology asset aldoxorubicin from a late-stage clinical asset to a partnered, pre-New Drug Application (NDA) candidate in the U.S.  In July 2017, CytRx announced a strategic licensing transaction with NantCell, Inc., for the global rights to aldoxorubicin.  Dr. Patrick Soon-Shiong, the CEO and founder of NantCell, developed, obtained regulatory approval for, and commercialized Abraxane®, another albumin-mediated cytotoxic agent which currently generates approximately $1B in annual sales.  CytRx believes that Dr. Soon-Shiong's track record and expertise with albumin-mediated agents will prove invaluable as NantCell works to obtain regulatory approval for aldoxorubicin, with the goal of commercialization thereafter.